NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome
Crossref DOI link: https://doi.org/10.1007/s12017-015-8341-2
Published Online: 2015-01-23
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Deacon, Robert M. J.
Glass, Larry
Snape, Mike
Hurley, Michael J.
Altimiras, Francisco J.
Biekofsky, Rodolfo R.
Cogram, Patricia
Text and Data Mining valid from 2015-01-23